IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia
Kush, Debra1; Kim, Hyo-Soo1,2; Hu, Da Yi3; Liu, Ji1; Sirah, Waheeda1; Sapre, Aditi1; Sisk, Christine McCrary1; Paolini, John F.1; Maccubbin, Darbie
关键词Extended-release niacin Flushing Laropiprant Primary hypercholesterolemia Mixed hyperlipidemia
刊名JOURNAL OF CLINICAL LIPIDOLOGY
2009-06-01
DOI10.1016/j.jacl.2009.04.048
3期:3页:179-186
收录类别SCI ; ISTP
文章类型Proceedings Paper
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]NICOTINIC-ACID ; NIACIN ; DYSLIPIDEMIA ; TRIAL ; TOLERABILITY ; CHOLESTEROL ; PREVENTION ; DISEASE ; SAFETY
英文摘要

BACKGROUND: Niacin has proven lipid-modifying efficacy and cardiovascular benefit; however, it is underused because of skin flushing, a process mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DPI) antagonist that mitigates niacin-induced flushing, has been combined with extended-release niacin (ERN) into a fixed-dose tablet containing I of ERN and 20 mg of LRPT (ERN/LRPT 1 g). In a large-scale (n = similar to 1600), multinational, 6-month study in dyslipidemic patients, ERN/LRPT 2 g produced superior lipid-modifying efficacy vs placebo, whether administered alone or with concomitant statins.

OBJECTIVE: This Phase III, randomized, double-blind study evaluated the lipid-modifying efficacy of ERN/LRPT alone or added to ongoing statins in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.

METHODS: After a 4-week placebo run-in, patients were randomized to ERN/LRPT I g (n = 322) or placebo (PBO; n = 324). After 4 weeks, the dose was advanced to 2 tablets/d (ERN/LRPT 2 g or PBO) for 8 additional weeks. End points included effects of ERN/LRPT 2 g vs P130 on low-density lipoprotein cholesterol (LDL-C; primary), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and other lipids/lipoproteins.

RESULTS: Relative to P130, ERN/LRPT 2 g produced significant (P<.001) changes in LDL-C 14.7%), HDL-C (15.9%), TG (-23.4%), LDL-C:HDL-C (-25.5%), non-HDL-C (-16.4%), apolipoprotein (Apo) B (-15.4%), and Apo A-I (5.3%) from baseline to week 12 in the total population. Similar results were observed in patients treated with ERN/LRPT alone or added to ongoing statin.

CONCLUSION: ERN/LRPT 2 g, administered alone or with a statin, produced significant improvements in multiple lipid/lipoprotein parameters in dyslipidemic Asian patients. (C) 2009 National Lipid Association. All rights reserved.

语种英语
WOS记录号WOS:000267614700005
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65175
专题北京大学第二临床医学院
作者单位1.Merck Res Labs, Rahway, NJ 07065 USA
2.Seoul Natl Univ Hosp, Seoul 110744, South Korea
3.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Kush, Debra,Kim, Hyo-Soo,Hu, Da Yi,et al. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia[J]. JOURNAL OF CLINICAL LIPIDOLOGY,2009,3(3):179-186.
APA Kush, Debra.,Kim, Hyo-Soo.,Hu, Da Yi.,Liu, Ji.,Sirah, Waheeda.,...&Maccubbin, Darbie.(2009).Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.JOURNAL OF CLINICAL LIPIDOLOGY,3(3),179-186.
MLA Kush, Debra,et al."Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia".JOURNAL OF CLINICAL LIPIDOLOGY 3.3(2009):179-186.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Kush, Debra]的文章
[Kim, Hyo-Soo]的文章
[Hu, Da Yi]的文章
百度学术
百度学术中相似的文章
[Kush, Debra]的文章
[Kim, Hyo-Soo]的文章
[Hu, Da Yi]的文章
必应学术
必应学术中相似的文章
[Kush, Debra]的文章
[Kim, Hyo-Soo]的文章
[Hu, Da Yi]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。